ATE229340T1 - Relaxinartiger faktor und damit zusammenhängende verfahren und verwendungen - Google Patents

Relaxinartiger faktor und damit zusammenhängende verfahren und verwendungen

Info

Publication number
ATE229340T1
ATE229340T1 AT96920364T AT96920364T ATE229340T1 AT E229340 T1 ATE229340 T1 AT E229340T1 AT 96920364 T AT96920364 T AT 96920364T AT 96920364 T AT96920364 T AT 96920364T AT E229340 T1 ATE229340 T1 AT E229340T1
Authority
AT
Austria
Prior art keywords
related methods
relaxing factor
factor
relaxin
analogs
Prior art date
Application number
AT96920364T
Other languages
English (en)
Inventor
Christian Schwabe
Elaine Unemori
Original Assignee
Connective Therapeutics Inc
Univ South Carolina
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Connective Therapeutics Inc, Univ South Carolina filed Critical Connective Therapeutics Inc
Application granted granted Critical
Publication of ATE229340T1 publication Critical patent/ATE229340T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/64—Relaxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT96920364T 1995-06-07 1996-05-16 Relaxinartiger faktor und damit zusammenhängende verfahren und verwendungen ATE229340T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/484,219 US5911997A (en) 1995-06-07 1995-06-07 Relaxin-like factor and methods and uses thereof
PCT/US1996/007399 WO1996040186A1 (en) 1995-06-07 1996-05-16 Relaxin-like factor and methods and uses thereof

Publications (1)

Publication Number Publication Date
ATE229340T1 true ATE229340T1 (de) 2002-12-15

Family

ID=23923245

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96920364T ATE229340T1 (de) 1995-06-07 1996-05-16 Relaxinartiger faktor und damit zusammenhängende verfahren und verwendungen

Country Status (9)

Country Link
US (2) US5911997A (de)
EP (1) EP0831871B1 (de)
JP (1) JP3830520B2 (de)
AT (1) ATE229340T1 (de)
AU (1) AU709115B2 (de)
CA (1) CA2224080C (de)
DE (1) DE69625354T2 (de)
ES (1) ES2188763T3 (de)
WO (1) WO1996040186A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2229479C (en) 1995-08-15 2010-03-30 Connective Therapeutics, Inc. Method of promoting angiogenesis
DE19641378C1 (de) * 1996-09-27 1998-04-02 Ihf Inst Fuer Hormon Und Fortp Diagnosehilfe sowie Verfahren zum Nachweis der Trächtigkeit von Wiederkäuern
GB9717652D0 (en) * 1997-08-20 1997-10-22 Nycomed Imaging As Method
AUPR814401A0 (en) 2001-10-08 2001-11-01 Howard Florey Institute Of Experimental Physiology And Medicine Human 3 relaxin
US20050186526A1 (en) * 2002-11-01 2005-08-25 Bas Medical, Inc. Methods and systems for enabling and stabilizing tooth movement
AU2003903124A0 (en) * 2003-06-20 2003-07-10 Mark Del Borgo Analogues of heteromeric proteins
US7878978B2 (en) * 2004-03-18 2011-02-01 University Of Pittsburgh- Of The Commonwealth System Of Higher Education Use of relaxin to increase arterial compliance
AU2005247332A1 (en) * 2004-04-30 2005-12-08 Corthera, Inc. Methods and compositions for control of fetal growth via modulation of relaxin
US20060052304A1 (en) * 2004-09-02 2006-03-09 Bas Medical, Inc. Method for remodeling bone and related sutures
EP1984016A1 (de) * 2006-02-17 2008-10-29 Associazione Foresta Per La Ricerca Nella Riproduzione Umana Verwendung von insulin-artigem faktor 3 zur behandlung von osteoporose und knochenerkrankungen
MX2011005454A (es) * 2008-11-24 2011-06-20 Corthera Inc Prediccion y prevencion de preeclampsia.
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
EP3572091B1 (de) 2010-08-17 2023-12-13 Ambrx, Inc. Modifizierte relaxinpolypeptide und deren verwendungen
EP2739647B1 (de) * 2011-08-04 2016-07-20 Relaxera GmbH & Co. KG i.G. c/o Immundiagnostik AG Verfahren zur herstellung von humanem relaxin-2
US20160152679A1 (en) * 2012-05-24 2016-06-02 Angion Biomedica Corp. Relaxin-like compounds and uses thereof
US9393288B2 (en) 2012-05-29 2016-07-19 The University Of Vermont And State Agricultural College Methods of treating diseases associated with PPARγ
WO2014040008A1 (en) * 2012-09-10 2014-03-13 Angion Biomedica Corp. Relaxin-like peptides and uses thereof
US10286078B2 (en) 2013-09-13 2019-05-14 The California Institute For Biomedical Research Modified therapeutic agents and compositions thereof
CA2933701C (en) 2013-12-18 2022-05-31 The California Institute For Biomedical Research Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof
MA41794A (fr) * 2015-03-18 2018-01-23 The California Institute For Biomedical Res Agents thérapeutiques modifiés et compositions associées
PT3387019T (pt) 2015-12-09 2022-01-14 Scripps Research Inst Proteínas de fusão de imunoglobulina de relaxina e métodos de uso
PE20191716A1 (es) 2017-02-08 2019-12-05 Bristol Myers Squibb Co Polipeptidos de relaxina modificada que comprenden un mejorador farmacocinetico y sus usos
CN117794946A (zh) 2021-06-09 2024-03-29 斯克利普斯研究所 长效双重gip/glp-1肽缀合物及使用方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0101309B1 (de) * 1982-08-12 1991-01-16 Howard Florey Institute Of Experimental Physiology And Medicine Molekulare Klonierung und Charakterisierung der das menschliche Relaxin kodierenden Gen-Sequenz
US4835251A (en) * 1986-06-23 1989-05-30 Genetech, Inc. Method of chain combination
US5166191A (en) * 1991-08-19 1992-11-24 Genentech, Inc. Use of relaxin in cardiovascular therapy
US5478807A (en) * 1991-08-19 1995-12-26 Genentech, Inc. Use of relaxin in the treatment of bradycardia

Also Published As

Publication number Publication date
AU5869996A (en) 1996-12-30
CA2224080C (en) 2010-07-27
US6949506B2 (en) 2005-09-27
US5911997A (en) 1999-06-15
JPH11512072A (ja) 1999-10-19
ES2188763T3 (es) 2003-07-01
JP3830520B2 (ja) 2006-10-04
EP0831871A1 (de) 1998-04-01
DE69625354T2 (de) 2003-10-30
EP0831871A4 (de) 1999-03-03
DE69625354D1 (de) 2003-01-23
EP0831871B1 (de) 2002-12-11
AU709115B2 (en) 1999-08-19
WO1996040186A1 (en) 1996-12-19
US20030158376A1 (en) 2003-08-21
CA2224080A1 (en) 1996-12-19

Similar Documents

Publication Publication Date Title
ATE229340T1 (de) Relaxinartiger faktor und damit zusammenhängende verfahren und verwendungen
ES2195970T3 (es) L-ribavirina y usos de la misma.
ATE225341T1 (de) In 6-position durch thio substituierte paclitaxele
DE69424517D1 (de) Gaserzeugende Zusammensetzungen
MX9203396A (es) Monohidrato de furoato de mometasona, proceso para producirlo y composiciones farmaceuticas.
BG102259A (en) Compostions with controlled paroxetine release
MX9804588A (es) Uso de composiciones que comprenden blanqueador de halogeno para suavidad mejorada a la piel.
NL1002835A1 (nl) Synergistisch stabilisatormengsel.
HU9402342D0 (en) Phosphono-oxymethyl-ethers of taxane derivatives
HUP9900936A1 (hu) Izocianátalapú készítmények, bevonatként történő alkalmazásuk és az így előállított bevonatok
ES2098921T3 (es) Composiciones de cetoconazol de uso topico.
MA24643A1 (fr) Tetrahydro-naphtalenes substitues et composes analogues
IS4404A (is) Afleiður steróla til stýringar rýrisskiptingu
ES2181744T3 (es) Hidratos de paclitaxel cristalinos.
BG99177A (bg) Нови 7 бета-заместени-4-аза-5 алфа-холестанони като инхибитори на 5 алфа-редуктаза
IL109720A (en) N-alkylthio polyamine derivatives and radioprotective compositions containing them
EA199800534A1 (ru) ПРИМЕНЕНИЕ 2-ЭТИЛГЕКСИЛ-α-ЦИАНО-β, β-ДИФЕНИЛАКРИАТА ДЛЯ УЛУЧШЕНИЯ СТАБИЛЬНОСТИ КОСМЕТИЧЕСКИХ КОМПОЗИЦИЙ, СОДЕРЖАЩИХ П-МЕТИЛБЕНЗИЛИДЕНКАМФОРУВ СОЧЕТАНИИ С ДИБЕНЗОИЛМЕТАНОВЫМ ПРОИЗВОДНЫМ
BG100248A (bg) Инхибитори на скваленсинтетаза
MX9602836A (es) MEZCLA QUE CONTIENE UNO O VARIOS ALFA-AMINOACIDOS Y SUS DERIVADOS, O AMBOS, Y UNO O VARIOS CICLOPENTANO- beta-AMINOACIDOS Y SUS DERIVADOS, O AMBOS.
DE60001366D1 (de) Orale zusammensetzung enthaltend perlit
BG104292A (en) Methods and compositions for the treatment of rheumatoid arthritis
MX9603199A (es) Antagonistas de receptores a endotelina.
BG102229A (en) Endothelium receptor antagonists
EA200000531A1 (ru) Применение кетолидов для профилактики тромботических артериальных осложнений, связанных с атеросклерозом
DK1189615T3 (da) Endoparasiticid synergistisk kombination indeholdende cykliske depsipeptider og piperaziner

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0831871

Country of ref document: EP